Journal
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Volume 106, Issue -, Pages 61-64Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2021.01.061
Keywords
SARS-CoV-2; Covid-19; Avidity; Protective immunity; Vaccination; Neutralizing antibody
Categories
Funding
- Medical Faculty of the University of Freiburg, Germany
Ask authors/readers for more resources
Avidity plays a crucial role in determining the strength of binding between IgG and its target epitope. The lack of high avidity IgG may lead to insufficient protective immunity. It is suggested to include avidity determination in evaluating vaccination protocols for SARS-CoV-2 to achieve truly protective immunity.
Background: Avidity is defined as the strength of binding between immunoglobulin G (IgG) and its specific target epitope. IgG of high avidity is established during affinity maturation. Failure to achieve high avidity IgG may result in a lack of protective immunity towards infection and disease. It is known that the interaction between SARS-CoV-2 spike protein and its cellular receptor is driven by high affinity. Therefore, it is predictable that protective antibodies towards SARS-CoV-2 should show high affinity/ avidity. Avidity after SARS-CoV-2 infection: Recent findings by several groups demonstrate that the serological response towards infection with SARS-CoV-2 and seasonal coronaviruses is characterized by incomplete avidity maturation, followed by a decline of the serological response. This response might facilitate reinfection, prevent herd immunity and potentially allow repeated cycles of infection. Consequences for vaccination towards SARS-CoV-2: Therefore, the sole focus on antibody titers reached after vaccination towards SARS-CoV-2 might not be sufficient to evaluate the degree of achieved protection. Rather, it is suggested to include avidity determination to optimize vaccination protocols and achieve high avidity IgG directed towards SARS-CoV-2 through vaccination. Avidity determination might also be useful to control for truly protective immunity towards SARS-CoV-2 in individual cases. (c) 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available